TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
51.15
-0.45 (-0.87%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close51.60
Open50.37
Bid36.32 x 800
Ask80.00 x 800
Day's Range48.61 - 53.00
52 Week Range24.21 - 67.54
Volume319,727
Avg. Volume504,332
Market Cap1.875B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.77
Earnings DateNov 03, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.00
  • GlobeNewswire

    Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and chief scientific officer effective March 2. Dr. Reich has over 25 years of pharmaceutical and biotech experience developing more than 20 drug candidates, including the approved drugs Viracept® for HIV and the tyrosine kinase inhibitor Inlyta® for the treatment of kidney cancer. Dr. Reich was most recently senior vice president of research and co-founder of eFFECTOR Therapeutics where he led discovery of three first-in-class small-molecule inhibitors, of MNK (tomivosertib), eIF4A (zotatifin), and eukaryotic initiation factor 4E (eIF4E).

  • GlobeNewswire

    Turning Point Therapeutics to Participate in Upcoming Investor Conferences

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Feb. 27 in New York and the Cowen 40th Annual Healthcare Conference on March 2 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics to Participate in Guggenheim Oncology Day

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Guggenheim Healthcare Talks Oncology Day in New York on Feb. 13. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of pharmaceutical and biotech oncology experience, including as the former president of Pfizer oncology where he led its global oncology franchise. “Garry brings deep expertise in oncology commercial strategy to the board at an important time for the company as we prepare for the potential commercialization of our lead asset,” said Dr. Sheila Gujrathi, chair of the Turning Point Therapeutics board.

  • GlobeNewswire

    Turning Point Therapeutics Announces Program Updates and Milestones for 2020

    Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site.

  • Benzinga

    The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • GlobeNewswire

    Turning Point Therapeutics Announces Management Transition

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that Dr. Jean Cui will step down as the company’s chief scientific officer for family reasons on Jan. 31. Dr. Cui will serve as a consultant and support the company during a transition period until June 30, 2020. “We are so grateful to Jean for all she has done as co-founder of the company, and we respect her decision to now prioritize her family’s needs,” said Dr. Athena Countouriotis, president and chief executive officer.

  • Are Insiders Buying Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Stock?
    Simply Wall St.

    Are Insiders Buying Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • GlobeNewswire

    Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs. In this role, Ms. Yeganegi will lead the global product development team responsible for Turning Point Therapeutics’ lead drug candidate, repotrectinib, and as head of Medical Affairs will support the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies.

  • The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK
    Zacks

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

  • 5 Best Performing IPOs of 2019
    Zacks

    5 Best Performing IPOs of 2019

    This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

  • Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the 38th annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2020. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%
    Zacks

    Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

    Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Weighing the Risk-Reward in Turning Point Therapeutics
    TheStreet.com

    Weighing the Risk-Reward in Turning Point Therapeutics

    During the Lightning Round segment of the Mad Money program callers get a chance to ask Jim Cramer about companies they are interested in. "This is a very speculative company and you need to do your homework," said Cramer. TPTX is a clinical-stage biopharmaceutical company that designs and develops small molecule, targeted oncology therapies.

  • GlobeNewswire

    Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

    SAN DIEGO, Nov. 12, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

  • GlobeNewswire

    Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

    SAN DIEGO, Nov. 11, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

  • The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
    Zacks

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

  • 4 Best-Performing IPOs So Far in 2019
    Zacks

    4 Best-Performing IPOs So Far in 2019

    Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

  • GlobeNewswire

    Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

    Registrational Phase 2 Study of Repotrectinib Ongoing  Phase 1/2 Clinical Studies of RET/SRC Inhibitor TPX-0046 and Repotrectinib in Pediatric Patients On Track to Initiate in.

  • GlobeNewswire

    Turning Point Therapeutics to Host Third Quarter 2019 Conference Call

    SAN DIEGO, Oct. 21, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report.

  • GlobeNewswire

    Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

    SAN DIEGO, Sept. 30, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

  • Is Failure in Store for the WeWork IPO?
    InvestorPlace

    Is Failure in Store for the WeWork IPO?

    WeWork parent The We Company has delayed the office-sharing startup's initial public offering until the end of the year. It now either won't come to the public market at all, or come at such a low valuation its venture backers will take a loss. This isn't terribly unusual for 2019.Source: Mitch Hutchinson / Shutterstock.com So far in 2019 there have been 94 IPOs, and 38 of them have shown negative returns.The big winners, like CrowdStrike Holdings (NASDAQ:CRWD), Beyond Meat (NASDAQ:BYND) and Zoom Video Telecommunications (NASDAQ:ZM), have generally come to the market prepared to make a profit. There have also been big medical winners with market caps near $1 billion, like ShockWave Medical (NASDAQ:SWAV) and Turning Point Therapeutics (NASDAQ:TPTX). Most IPOs are still hits -- but the batting average is declining like an aging slugger's.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWeWork is distinguished by the same flaws as Uber (NYSE:UBER) stock and Lyft (NASDAQ:LYFT) stock. It's not making money, even at scale, and current investors are looking at you for a bailout. The WeWork ProblemWeWork's model is to buy lots of office space, fix it up, then sell it at retail in the form of "memberships." As I wrote in August, it's more like LA Fitness than Cloudflare (NYSE:NET), which went public Sept. 13 and is already showing a 25% return. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Worse, WeWork's business model is not unique. IWG (OTCMKTS:IWGFF), founded in Belgium back in 1989, has been operating in low-cost suburban office parks for years. It came public at the end of 2016 and only proved itself this year. IWGFF stock is up 92% year-to-date.The difference is that IWG has a market cap of $4.8 billion. WeWork was initially seeking a market cap of $47 billion. Worse, WeWork needs the $3 billion it was trying to raise in order to secure the $6 billion line of credit in order to keep operating.The business model is based on a myth of young workers with startups signing up for prestige "co-working spaces" dressed up with amenities they like. In fact, WeWork has mainly signed up established tech companies seeking contingency space like Salesforce (NYSE:CRM), Cisco (NASDAQ:CSCO) and Facebook (NASDAQ:FB). It's expansion insurance. CEO Adam NeumannMeanwhile t-shirted CEO Adam Neumann has come off as something of a fraud. He isn't a dweeby kid. He's a 40-year old Israeli military veteran who spent big money before earning a dime for shareholders. He tried to score $5.9 million from his own company for trademarking the word "We." This is also a mom-and-pop operation; co-founder Miguel McKelvey gets only six mentions in the U.S. Securities and Exchange Commission Form S-1, against 20 mentions for Neumann's wife Rebekah.While portraying a handsome young family man on TV, Neumann also created a fraternity culture that drew a sexual harassment suit last year.Worse, it's clear the business model is not yet working. WeWork lost $1.9 billion in 2018, then another $904 million for the first six months of 2019, on revenue of $1.5 billion. The Bottom Line on the WeWork IPOThe real loser is SoftBank (OTCMKTS:SFTBF) and its Vision Fund. It brought $100 billion to the party in order control the technology of the future -- and it's trying to raise another $100 billion. SoftBank founder Masayoshi Son runs the fund, but the money is mostly from sovereign wealth funds in Saudi Arabia and the United Arab Emirates.Son's losers, in addition to WeWork, include Uber, Sprint (NYSE:S) and Slack (NYSE:WORK), which is down more than 30% after coming public in June. Son has called his Vision Fund the ultimate disruptor, but it may be Son who turns out to be the greater fool.Dana Blankenhorn is a financial and technology journalist. He is the author of the mystery thriller, The Reluctant Detective Finds Her Family, available at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Is Failure in Store for the WeWork IPO? appeared first on InvestorPlace.